N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-imidazol-1-ylmethyl-benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-imidazol-1-ylmethyl-benzamide
• 英文别名: N-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(imidazol-1-ylmethyl)benzamide
• 化学式: C₂₀H₂₃N₅O₂
• 分子量: 365.435
• InChiKey: USQYDMLPDUTMBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  99.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-bromomethyl-benzamide 、 咪唑钠 以 四氢呋喃 为溶剂， 生成 N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-imidazol-1-ylmethyl-benzamide
  参考文献：
  名称：

  Dipeptide nitriles

  摘要：

  N-末端取代二肽腈可作为半胱氨酸蛋白酶抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗依赖于半胱氨酸蛋白酶的疾病和症状，包括炎症、类风湿关节炎、骨关节炎、骨质疏松、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽腈化合物为公式I的化合物，或其生理上可接受和可裂解的酯或盐，其中：符号如定义。特别是发现通过适当选择基团R、R2、R3、R4、R5、X1、Y和L，可以改变化合物作为各种半胱氨酸蛋白酶类型抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，可改变，例如获得选择性抑制特定蛋白酶类型或蛋白酶类型组合的抑制剂。

  公开号：

  US06353017B1

文献信息

• Dipeptide derivatives
  申请人：——

  公开号：US20040110806A1

  公开（公告）日：2004-06-10

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof 1 wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代的二肽硝基化合物可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿性关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽硝基化合物是公式I的化合物，或其生理上可接受和可分解酯或其盐，其中：符号的定义如上所述。特别是，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为不同半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• DIPEPTIDE NITRILES
  申请人：Altmann Eva

  公开号：US20080027060A1

  公开（公告）日：2008-01-31

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽基腈可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽基腈化合物为I式化合物，或其生理上可接受和可水解酯或其盐。其中：符号如定义。特别地，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• US6353017B1
  申请人：——

  公开号：US6353017B1

  公开（公告）日：2002-03-05
• Dipeptide nitriles
  申请人：Novartis AG

  公开号：US06353017B1

  公开（公告）日：2002-03-05

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽腈可作为半胱氨酸蛋白酶抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗依赖于半胱氨酸蛋白酶的疾病和症状，包括炎症、类风湿关节炎、骨关节炎、骨质疏松、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉粥样硬化（包括动脉粥样硬化斑块破裂和不稳定）。特定的二肽腈化合物为公式I的化合物，或其生理上可接受和可裂解的酯或盐，其中：符号如定义。特别是发现通过适当选择基团R、R2、R3、R4、R5、X1、Y和L，可以改变化合物作为各种半胱氨酸蛋白酶类型抑制剂的相对选择性，例如半胱氨酸蛋白酶B、K、L和S，可改变，例如获得选择性抑制特定蛋白酶类型或蛋白酶类型组合的抑制剂。